RAPGEF1

Across TCGA pan-cancer cohorts, RAPGEF1 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated RAPGEF1 data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher RAPGEF1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RAPGEF1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SCLC show a favorable association.

BRCA, CESC, and LUSC are the cancer types where RAPGEF1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.594	0.925	<.001	37	view →
CESC	OS	Median	II,III,IV	0.170	0.764	<.001	14	view →
LUSC	DFS	Median	II,III,IV	0.130	0.760	<.001	12	view →
SARC	DFS	Median	All	0.177	0.612	.021	11	view →
ACC	OS	Median	All	0.158	0.632	.012	9	view →
THCA	DFS	Median	All	0.089	0.841	.003	6	view →
UCEC	DFS	Median	II,III,IV	0.881	0.434	.034	4	view →
SCLC	OS	Median	II,III,IV	1.000	0.521	.042	2	view →
COAD	OS	Median	II,III,IV	0.271	0.683	.049	2	view →
SKCM	OS	Median	All	0.726	0.871	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

RAPGEF1–BRCA (OS)

Open the BRCA breakdown →